ArticleInternational journal of clinical oncology2023

Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.

Ryosuke Kumanishi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.